Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,893 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapeutic insulin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Role of TLR4 on Lipid-induced Insulin Resistance

NCT02321111
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Eritoran, D5W (5% Dextrose in water)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Completed No phase listed Observational

Telehealth and Meal Replacement Pilot Program for Patients With Diabetes

NCT04885621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
nutrisystem-D
Dietary Supplement
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 30, 2026, 7:24 PM EDT
Completed No phase listed Observational

Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts

NCT00001878
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 7:24 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effect of EGCG on the Body's Response to Insulin

NCT00434499
View directory record Official record
Conditions
Hypertension, Obesity, Type 2 Diabetes, Insulin Resistance
Interventions
EGCG
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

NCT00325364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Injectable insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Sacramento, California • Santa Ana, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Load, Metabolism & Obesity in Pregnancy

NCT01287299
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Low Glycemic Load diet, Low Fat Diet
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protection Against Insulin Resistance in Obesity

NCT02717832
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
hyperinsulinemic-euglycemic clamp
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Performance of an Investigational Blood Glucose Monitoring System

NCT01824355
View directory record Official record
Conditions
Diabetes
Interventions
Ninja 3 PLUS Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 30, 2026, 7:24 PM EDT
Terminated Not applicable Interventional Results available

Glucose Control In Hematopoetic Stem Cell Transplant

NCT00582036
View directory record Official record
Conditions
Hyperglycemia, Hematopoietic Stem Cell Transplantation
Interventions
Regular Insulin, Deployment of the MiniMed Paradigm monitoring device
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 30, 2026, 7:24 PM EDT
Terminated Not applicable Interventional

High-intensity Interval Training for Obese Individuals

NCT04075799
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
high-intensity interval training
Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Dose Response for Improving Insulin Sensitivity

NCT01452035
View directory record Official record
Conditions
Obesity
Interventions
Exercise
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

TAK-329 Glucose Clamp Study

NCT01311076
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
TAK-329, Insulin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 50 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Sep 30, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans

NCT02490124
View directory record Official record
Conditions
Diabetes Type 1
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Sleep Loss and Mechanisms of Impaired Glucose Metabolism

NCT00555750
View directory record Official record
Conditions
Primary Insomnia
Interventions
eszopiclone, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men

NCT00470990
View directory record Official record
Conditions
Hypogonadism
Interventions
GnRH antagonist (Acyline)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Vitamin D Deficiency and Vitamin D Supplementation on Glucose Metabolism

NCT00749918
View directory record Official record
Conditions
Prediabetes, Vitamin D Deficiency
Interventions
Cholecalciferol (vitamin D3)
Dietary Supplement
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 4 Interventional

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

NCT00006190
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Nelfinavir mesylate, Stavudine, Lamivudine, Efavirenz
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans

NCT03077360
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes, Obesity
Interventions
Lifestyle
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 50 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional

The Effects of Strawberries on Blood Cholesterol.

NCT03441620
View directory record Official record
Conditions
Hyper-LDL-cholesterolemia, Metabolic Syndrome
Interventions
strawberries, Control powder
Dietary Supplement · Other
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Las Vegas, Nevada • Oklahoma City, Oklahoma • Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 30, 2026, 7:24 PM EDT